Close Menu

NEW YORK – New drugs are more likely to be approved if they target a gene linked to disease, according to a new analysis from AbbVie researchers that confirms earlier findings. 

Only between 5 percent and 10 percent of new drug candidates that enter early-stage clinical trials are eventually approved. In 2015, researchers led by GlaxoSmithKline's Philippe Sanseau reported that drugs with supporting genetic evidence were twice as likely to be approved.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.